![]() Reprinted with permission by First Databank, Inc. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers WAC represents a published catalogue or list price and may not represent an actual transactional price. Approximate wholesale acquisition cost (WAC).A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Boehringer Ingelheim Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Praxbind (idarucizumab) as a specific reversal agent for Pradaxa (dabigatran etexilate mesylate). ![]() Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Food and Drug Administration) approved medication manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. The FDA granted accelerated approval to Praxbind in October 2015, with continued approval contingent upon results from the phase III RE-VERSE AD trial, the largest study to investigate a reversal agent for a NOAC. Edoxaban (Savaysa) – the fourth new oral anticoagulant.Dabigatran etexilate (Pradaxa) - a new oral anticoagulant.
0 Comments
Leave a Reply. |